China Medical System (00867) said its wholly-owned subsidiary CMS Pharma has entered into an asset purchase agreement with DKSHI, a company incorporated in Switzerland.
Pursuant to which CMS Pharma agreed to purchase from DKSHI, with respect to "Combizym" in China, HK and Switzerland, and certain other designated countries or areas in Asia, and with respect to "Hirudoid" in China, including (1) all trademarks regarding the products; (2) all market authorizations or similar licenses, certificates or approvals regarding the
products in the territory and all rights, benefits or other interests obtained; (3) the
exclusive right and title to develop, manufacture, register, apply for registration, import, market, distribute, sell or otherwise use and/or exploit the products; and (4) all books and records, commercial information and medical information related to the products.
The total consideration for the purchased assets is CHF76.6 million payable in cash.
Combizym is used for the treatment of digestion caused by a decrease in digestive enzymes. Hirudoid is used for the treatment of various phlebitis, soft tissue injuries
and also used as an adjuvant therapy for varicose veins surgery and postoperative
sclerotherapy.
etnet榮獲HKEX Awards 2023 「最佳表現證券數據供應商」大獎► 了解詳情
